Bruker Past Earnings Performance

Past criteria checks 6/6

Bruker has been growing earnings at an average annual rate of 16.4%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 8.7% per year. Bruker's return on equity is 30.3%, and it has net margins of 14.4%.

Key information

16.4%

Earnings growth rate

17.8%

EPS growth rate

Life Sciences Industry Growth	21.5%
Revenue growth rate	8.7%
Return on equity	30.3%
Net Margin	14.4%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Apr 11

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Aug 09

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 27

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Jul 11

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Jun 26

Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Apr 25

These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well

Apr 07

Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth

Feb 20

Why Bruker Corporation (NASDAQ:BRKR) Could Be Worth Watching

Jan 17

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Dec 30

Should You Think About Buying Bruker Corporation (NASDAQ:BRKR) Now?

Oct 16

Here's Why We Think Bruker (NASDAQ:BRKR) Is Well Worth Watching

Oct 03

Estimating The Intrinsic Value Of Bruker Corporation (NASDAQ:BRKR)

Sep 19

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Sep 05

Bruker Corporation: Upside Is Limited From Here

Aug 24

Bruker declares $0.05 dividend

Aug 12

Revenue & Expenses Breakdown
Beta

How Bruker makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:BRKR Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	2,965	427	730	295
30 Sep 23	2,818	319	687	275
30 Jun 23	2,715	319	644	260
31 Mar 23	2,621	312	625	248
31 Dec 22	2,531	297	608	236
30 Sep 22	2,506	275	598	231
30 Jun 22	2,476	274	605	226
31 Mar 22	2,458	282	577	223
31 Dec 21	2,418	277	563	221
30 Sep 21	2,362	270	544	220
30 Jun 21	2,264	238	518	216
31 Mar 21	2,118	204	485	204
31 Dec 20	1,988	158	472	198
30 Sep 20	1,960	158	470	188
30 Jun 20	1,970	165	480	185
31 Mar 20	2,035	177	503	190
31 Dec 19	2,073	197	500	188
30 Sep 19	2,026	207	491	186
30 Jun 19	1,972	189	473	182
31 Mar 19	1,925	184	459	177
31 Dec 18	1,896	180	449	173
30 Sep 18	1,873	98	443	172
30 Jun 18	1,842	92	440	171
31 Mar 18	1,813	84	432	167
31 Dec 17	1,766	79	420	162
30 Sep 17	1,706	151	407	157
30 Jun 17	1,664	161	399	154
31 Mar 17	1,621	152	396	151
31 Dec 16	1,611	154	394	148
30 Sep 16	1,619	146	393	148
30 Jun 16	1,621	111	393	144
31 Mar 16	1,646	119	390	145
31 Dec 15	1,624	102	392	146
30 Sep 15	1,654	66	408	151
30 Jun 15	1,677	60	420	158
31 Mar 15	1,739	55	436	165
31 Dec 14	1,809	57	451	174
30 Sep 14	1,853	66	451	182
30 Jun 14	1,872	77	449	185
31 Mar 14	1,870	83	441	187
31 Dec 13	1,839	80	438	191
30 Sep 13	1,805	58	444	192
30 Jun 13	1,813	81	439	191

Quality Earnings: BRKR has high quality earnings.

Growing Profit Margin: BRKR's current net profit margins (14.4%) are higher than last year (11.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BRKR's earnings have grown by 16.4% per year over the past 5 years.

Accelerating Growth: BRKR's earnings growth over the past year (44%) exceeds its 5-year average (16.4% per year).

Earnings vs Industry: BRKR earnings growth over the past year (44%) exceeded the Life Sciences industry -9.3%.

Return on Equity

High ROE: BRKR's Return on Equity (30.3%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Bruker Past Earnings Performance

Past criteria checks 6/6

Key information

Recent past performance updates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bruker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Recent updates

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Insider notifies of intention to sell stock

Fourth quarter dividend of US$0.05 announced

Consensus EPS estimates increase by 25%

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Price target increased by 14% to US$84.55

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Price target decreased by 11% to US$70.56

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman exercised options to buy US$3.4m worth of stock.

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Price target decreased by 8.7% to US$80.89

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Insufficient new directors

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Chairman notifies of intention to sell stock

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chairman exercised options to buy US$4.9m worth of stock.

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Bruker Corporation to Report Q2, 2023 Results on Aug 03, 2023

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Bruker Announces SciY Platform of Advanced Scientific and Automation Software Solutions for the Digital Transformation of the Life Science and Biopharma Industries

Bruker Corporation Announces New D6 PHASER Benchtop X-Ray Diffraction Platform for Materials Analysis and Advanced Research

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Executive VP & CFO recently sold US$1.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target increased by 7.7% to US$88.78

Bruker CorporationIntroduces Novel EVOQ™ DART-TQ+ for Chromatography-Free Mass Spectrometry Aimed at the Applied Market Segments

Independent Director recently sold US$838k worth of stock

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) announces an Equity Buyback for $500 million worth of its shares.

Bruker Corporation (NasdaqGS:BRKR) acquired ZONTAL, Inc.

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman notifies of intention to sell stock

Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Price target increased by 7.5% to US$79.56

These 4 Measures Indicate That Bruker (NASDAQ:BRKR) Is Using Debt Reasonably Well

Bruker (NASDAQ:BRKR) Ticks All The Boxes When It Comes To Earnings Growth

Bruker Corporation Approves Quarterly Dividend, Payable on March 17, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Bruker Corporation to Report Q4, 2022 Results on Feb 09, 2023

Revenue & Expenses Breakdown
Beta